Symbiotec Pharmalab IPO Opens: Price Band, GMP and Key Investment Factors

Symbiotec Pharmalab IPO Opens: Price Band, GMP and Key Investment Factors

Symbiotec Pharmalab has opened its ₹1,757 crore initial public offering (IPO) for public subscription, drawing strong attention from investors and the pharmaceutical market. The IPO opened on August 24, 2026, and will close on August 27, 2026. The company plans to list its shares on the BSE and NSE on September 1, subject to the final schedule.

Symbiotec Pharmalab IPO: Key Details

Particulars	Details
IPO Opening Date	August 24, 2026
IPO Closing Date	August 27, 2026
Issue Size	₹1,757 Crore
Price Band	₹938–₹988 per share
Fresh Issue	₹150 Crore
Offer for Sale	₹1,607 Crore
Lot Size	15 Shares
Minimum Investment	₹14,820
Expected Listing	September 1, 2026
Stock Exchanges	BSE and NSE

Symbiotec Pharmalab IPO GMP

The grey market has also generated strong interest. Market trackers reported GMP levels ranging from roughly ₹345 to ₹409 per share on the opening day.

At the higher end, this indicated a potential premium of around 40% over the ₹988 upper price band. However, GMP remains unofficial and unregulated. It reflects market sentiment but does not guarantee the actual listing price.

Note: GMP can change rapidly depending on market conditions and investor demand.

Also Read: Madhur Knit Crafts IPO: Financials and Investor Outlook

About Symbiotec Pharmalab

Symbiotec Pharmalab operates in the pharmaceutical and biotechnology sector. The company develops and manufactures active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products.

It has built a strong presence in international markets, with more than two-thirds of its revenue coming from overseas business. The company also holds regulatory approvals from major global authorities, supporting its access to regulated markets.

Symbiotec Pharmalab Financial Performance

Particulars (₹ Crore)	FY24	FY25	FY26
Total Income	723.33	755.98	872.26
Profit Before Tax	130.98	146.98	153.36
Profit After Tax	100.06	96.79	109.90
EBITDA	177.04	206.11	231.97
Total Debt/Borrowings	247.21	540.92	387.91
Net Worth	720.68	821.15	1,158.64
Total Assets	1,294.79	1,579.65	1,780.79

Key Strengths of Symbiotec Pharmalab

Strong manufacturing and specialised product portfolio.
Significant revenue from international markets.
Global customer base and regulatory approvals.
Strong anchor investor participation.

Key Risks Investors Should Consider

Top five products contribute nearly 63% of revenue.
Regulatory changes may affect business operations.
Competition may create pricing and margin pressure.
High dependence on international markets.

Conclusion

Symbiotec Pharmalab IPO has attracted attention through strong GMP, anchor investor participation and its global pharmaceutical business. However, product concentration and regulatory risks remain important concerns. Investors seeking potential long-term growth should study valuation and financial performance carefully, while short-term applicants should remember that GMP does not guarantee listing gains.

FAQs

1. When does the Symbiotec Pharmalab IPO open and close?

Ans: The IPO opened on August 24, 2026, and is scheduled to close on August 27, 2026.

2. What is the price band of the IPO?

Ans: The price band is ₹938 to ₹988 per equity share.

3. What is the total issue size?

Ans: The total IPO size is ₹1,757 crore, including a ₹150 crore fresh issue and an approximately ₹1,607 crore offer for sale.

4. What is the minimum investment required?

Ans: Investors need to apply for at least 15 shares, requiring ₹14,820 at the upper price band.

5. What is the latest GMP?

Ans: The GMP is around ₹345–₹409, but it can change with market sentiment.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult a qualified financial advisor before making any investment decision.